Business
Liquidia Announces Poster Presentation at the 14th Annual World Congress of the Pulmonary Vascular Research Institute (PVRI)
RESEARCH TRIANGLE PARK, N.C., Jan. 24, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical
About this update from Liquidia Corporation
[{"type":"text","content":"RESEARCH TRIANGLE PARK, N.C., Jan. 24, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary PRINT® technology, today announced that it will present a poster highlighting clinical data from studies of LIQ861, treprostinil inhalation powder, to support the treatment of pulmonary arterial hypertension (PAH) at the 14th PVRI Annual World Congress on Pulmonary Vascular Disease in Lima, Peru.\n Presentation details are as follows: Title: Pharmacokinetic (PK) performance of LIQ861 and evaluation of comparative bioavailability with Tyvaso® in healthy subjects Abstract Reference Number: 50 Date/Time: Friday, January 31; 11:40 a.m. – 1:00 p.m. ET Location: Grand Salon 1 A copy of the poster will be available on the company’s website at the time of the presentation. About LIQ861 LIQ861 is an inhaled dry powder formulation of treprostinil designed using Liquidia’s PRINT® technology to enhance deep-lung delivery using a convenient, palm-sized dry powder inhaler (“DPI”) for the treatment of pulmonary arterial hypertension (PAH). PRINT® technology enables development of drug particles that are precise and uniform in size, shape, weight and composition that are engineered for optimal deposition in the lung following oral inhalation. Liquidia believes LIQ861 can overcome the limitations of current inhaled therapies and has the potential to maximize the therapeutic benefits of treprostinil in treating PAH by safely delivering higher doses into the lungs. Liquidia has completed an open-label, multi-center phase 3 clinical study of LIQ861 in patients diagnosed with PAH known as INSPIRE, or Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil. About Liquidia Liquidia is a late-stage clinical biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary PRINT® technology to transform the lives of patients. Currently, Liquidia is focused on the development of two product candidates using its PRINT particle engineering platform: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Having been evaluated in a phase 3 clinical trial (INSPIRE), LIQ8...